Drug Type Small molecule drug |
Synonyms (1S,2S,6S)-6-((S)-5-chloro-6-fluoro-2-phenyl-2-((S)-pyrrolidin-2-yl)-2,3-dihydrobenzofuran-4-yl)-7-fluoro-1-hydroxy-N,2-dimethyl-2,3-dihydro-1H-indene-5-carboxamide |
Target |
Action inhibitors |
Mechanism TEAD inhibitors(TEA domain transcription factors inhibitors), YAP1 inhibitors(Yes1 associated transcriptional regulator inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | IND Approval | China | 30 Jul 2024 | |
Malignant Pleural Mesothelioma | IND Approval | China | 30 Jul 2024 |